Skip to main content
Premium Trial:

Request an Annual Quote

Prodesse to Remove Three ASRs From US Market, Submit Them for FDA OK

NEW YORK (GenomeWeb News) — Prodesse said today it will stop selling three of its multiplex ASR products in the US Aug. 1 as it transitions them into in vitro diagnostics in light of a recent US Food and Drug Administration draft guidance.
 
The company said it plans to remove the underlying supermixes for its Hexaplex, Hexaplex Plus, and ProPneumo-1 products as part of an “orderly transition” from ASRs to IVD assays.
 
“Though the actual ASR regulations have not changed, the September 2006 ASR draft guidance documents clearly show that the FDA’s posture towards ASRs has changed,” Prodesse CEO Tom Shannon said in a statement.
 
”Our company prefers to clear up any ambiguity in our customers' minds by moving from ASRs to IVDs,” Shannon added.
 
The company said its ProFlu+ test for influenza A, B, and RSV has completed clinical trials and a 510(k) application will “shortly” be submitted for FDA clearance.
 
The FDA has also received a pre-IDE submission on Prodesse’s Pro hMPV+ test for human metapneumovirus. More studies are in the planning stages, Prodesse said.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.